| A118 |
Tezepelumab
Featured
|
Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma. |
|
| A119 |
Aducanumab
Featured
|
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research. |
|
| A117 |
Lecanemab
Featured
|
Lecanemab (Mouse IGG2a) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease. |
|
| A113 |
Acapatamab Biosimilar
Featured
|
Acapatamab (AMG-160) is an anti-CD3E/FOLH1 monoclonal antibody. |
|
| DC67091 |
Adenosine A1 receptor activator T62
Featured
|
Adenosine A1 receptor activator T62 is an allosteric enhancer of adenosine A1 receptor. Adenosine A1 receptor activator T62 produces antinociception in animal models of acute pain and also reduces hypersensitivity in models of inflammatory and nerve-injury pain. |
|
| DC67092 |
2,6-Heptadienoic acid, 4-ethyl-, (2E)-
Featured
|
|
|
| DC67093 |
Benzoic acid, 3-fluoro-, (2E)-2-[(4-hydroxy-3,5-diiodophenyl)methylene]hydrazide
Featured
|
|
|
| DC67094 |
JNJ-39758979 2HCl
Featured
|
JNJ-39758979 2HCl is an antagonist of histamine receptor H4. |
.png)
|
| A216 |
Anrukinzumab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Anrukinzumab (IMA-638) is a humanized anti-IL-13 monoclonal antibody. Anrukinzumab effectively reduces lung inflammation in a cynomolgus monkey model. Anrukinzumab can be used in studies of ulcerative colitis (UC) as well as asthma. |
.png)
|
| A293 |
BMS patent anti-Integrin α5β1
Featured
|
|
|
| DC67095 |
PAM-Acid |
|
|
| DC67096 |
DMG-PEG2000-NHS |
DMG-PEG2000-NHS is a PEG derivative that can be used in various biomedical applications, such as the construction of drug delivery systems (siRNA delivery liposomes, lipid nanoparticle, etc.). The active ester (NHS) can react with an amino group (-NH2) to form a stable amide bond, which can be used as a linker in a bioconjugation strategy to modify amino-linked peptide proteins as well as other small molecules. |
|
| DC67097 |
DSPE-PEG(2000)-amine (sodium salt)
Featured
|
DSPE-PEG(2000)-amine is a PEGylated derivative of 1,2-distearoyl-sn-glycero-3-PE (DSPE; Item No. 15095). It has been used in the synthesis of solid lipid and thermosensitive liposomal nanoparticles for the delivery of anticancer agents. DSPE-PEG(2000)-amine has also been used in the synthesis of fluorescein isothiocyanate-loaded mesoporous silica nanoparticles for imaging applications.4 It can be conjugated to a variety of functional molecules for improved cellular targeting and uptake of DSPE-PEG(2000)-amine-containing nanoparticles. |
|
| DC67098 |
cis-AGB1
Featured
|
Cis-AGB1 is a negative control for AGB1 . Exhibits no significant VHL binding affinity. |
|
| DC60698 |
Compound 3 (AKT1/E17K inhibitor)
Featured
|
Compound 3 (AKT1/E17K inhibitor) is an allosteric, lysine-targeted salicylaldehyde, AKT1 (E17K) inhibitors with IC50 of 0.6 nM and shows 28-fold and 103-fold selectivity over AKT1 (WT) and AKT2 (WT), respectively. |
|
| DC60699 |
MS105
Featured
|
MS105 is a potent PTK6 PROTAC degrader. MS105 effectively reduces PTK6 protein levels, induces apoptosis, and inhibits growth and migration of breast cancer cell lines of diverse subtypes. |
|
| DC60700 |
ACR-2316
Featured
|
ACR-2316 is a potentially first-in-class, potent, selective WEE1/PKMYT1 inhibitor with IC50 of 2 nM/44 nM. ACR-2316 demonstrates greater potency in all cell lines tested compared to adavosertib and lunresertib. |
|
| DC60701 |
ZZ3
Featured
|
ZZ3 is a potent CDK12/13 molecular glue degrader with DC50 of 35 nM and 57 nM, respectively. |
|
| A379 |
Genentech patent anti-Notch3
Featured
|
|
|
| DC60702 |
31hP |
31hP is an asymmetric A3-lipid for mRNA delivery. 31hP LNP exhibits higher stability and durability compared with MC3 LNP and SM-102 LNP. 31hP LNP achieves more efficient hepatic mRNA delivery with a much higher gene editing efficiency than MC3 LNP and LP01 LNP. |
|
| DC67099 |
somatostatin GMP grade
Featured
|
Somatostatin is a tetradecapeptide which can suppress the growth hormone (GH) secretion and control the pituitary hormone secretion in human CNS. |
.gif)
|
| DC67100 |
Cetrorelix GMP grade
Featured
|
Cetrorelix is a potent gonadotrophin-releasing hormone (GnRH) antagonist. Cetrorelix inhibits the endogenous luteinizing hormone surge during ovarian stimulation. Cetrorelix reduces cyclophosphamide induced ovarian follicular destruction in mice. |
|
| DC67101 |
Ganirelix acetate GMP grade
Featured
|
Ganirelix acetate is an antagonist of GnRH that competitively antagonizes the gonadotropic GnRH receptor, thereby mutating the pathway and causing rapid and reversible inhibition of gonadotropin (luteinizing hormone LH and follicle stimulating hormone FSH) secretion. Ganirelix Acetate acts by competitively blocking the GnRH receptors on the pituitary gonadotroph and subsequent transduction pathway. It induces a rapid, reversible suppression of gonadotropin secretion. The suppression of pituitary LH secretion by Ganirelix Acetate is more pronounced than that of FSH. |
|
| A449 |
Cofetuzumab
Featured
|
Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is usually CHO (Chinese Hamster Ovary) cells. |
|
| A450 |
Apamistamab
Featured
|
|
|
| A451 |
Novartis patent anti-CD45
Featured
|
|
|
| A452 |
Ntx1088
Featured
|
|
|
| A453 |
GSK-4381562
Featured
|
|
|
| A454 |
Anti-PVRIG Antibody (COM701)
Featured
|
|
|
| A455 |
Foravirumab
Featured
|
Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III. |
|
